A heart-outcomes trial, not a weight-loss contest
The most useful question about a medicine is sometimes broader than how much weight participants lost. SELECT asked whether semaglutide reduced major cardiovascular events in a specific higher-risk population. That distinction changes how the evidence should be used: a heart-outcomes result deserves to be read on its own terms, with the participants and comparison kept visible.
The randomized, double-blind SELECT trial enrolled 17,604 adults aged at least 45, with established cardiovascular disease, a BMI of at least 27 and no diabetes. It compared weekly subcutaneous semaglutide 2.4 mg with placebo. Average follow-up was 39.8 months; Novo Nordisk funded the research.[1]
Put relative and absolute benefit together
The primary endpoint combined cardiovascular death, nonfatal heart attack and nonfatal stroke. An event occurred in 6.5% of the semaglutide group and 8.0% of the placebo group; the hazard ratio was 0.80, with a 95% confidence interval of 0.72–0.90.
SELECT: observed event proportions over average follow-up of 39.8 months. Common zero baseline; 0–10% scale.
The often-quoted 20% reduction describes the relative hazard, not a 20 percentage-point drop in the chance of an event. Subtracting the rounded observed percentages gives a 1.5 percentage-point difference, approximately 15 fewer people with an event per 1,000 participants over this follow-up. That is descriptive arithmetic, not an individualized forecast.
For the weight-loss question, see the semaglutide–tirzepatide head-to-head trial. If you are comparing access, start with providers offering insurance support.
Why the denominator changes the story
| Measure | Meaning | Important boundary |
|---|---|---|
| Hazard ratio: 0.80 | Lower event hazard in the semaglutide group | Includes event timing; not identical to a simple risk ratio. |
| Observed difference: 1.5 percentage points | 8.0% minus 6.5% | Uses rounded proportions across the trial follow-up. |
| Approximately 15 per 1,000 | A translation of the absolute difference | Not an annual rate or a prediction for a lower-risk population. |
Relative effects can sound large while hiding how common an event was to begin with. Absolute effects reveal that baseline context, but also need a time horizon. A number without the population and the follow-up is incomplete. For a person with a different medical history, the starting risk may differ substantially; this study alone cannot supply their personal benefit estimate.
The combined endpoint is another boundary. A result for a composite of three events does not automatically mean the same proportional benefit for every component. When a claim singles out one outcome, look for the analysis of that outcome rather than assuming the headline applies unchanged.
Benefit belongs beside treatment burden
Adverse events led to permanent treatment discontinuation in 16.6% of the semaglutide group versus 8.2% with placebo. This is an important counterweight to discussing benefit alone. It does not mean that every discontinuation was equally severe, and it does not supply a personal probability of intolerance.
In 2024, the FDA approved a Wegovy indication to reduce cardiovascular death, heart attack and stroke in adults with cardiovascular disease and overweight or obesity, alongside reduced-calorie eating and increased physical activity.[2] The authorized product and indication matter; an ingredient name on another preparation is not enough to transfer that regulatory conclusion.
This article summarizes evidence, not eligibility. A clinician needs to consider the full prescribing information, contraindications, other medicines and the person’s goals. The original SELECT population should also stay distinct from the wording of the approved indication; a study description and a prescribing label serve different purposes.
What to ask before choosing a service
Start by asking whether cardiovascular prevention is relevant to your care plan and how the evidence fits your history. Ask which clinician coordinates treatment with your existing care team, how records are shared, and who handles concerns between visits. A convenient enrollment process is only one part of the service.
If insurance support matters, our insurance-support shortlist and Form Health review help frame questions about appointments and coverage. They do not establish that a particular provider delivers SELECT-level outcomes. Insurance approval, product availability and a clinical prescription remain separate decisions.
Request the exact medicine name in the written offer and separate medication charges from visits or membership. The quote tool can help compare those amounts on a common time basis. It cannot value a health benefit or determine whether two proposed treatments are equivalent. Keeping that distinction clear makes the research more useful, rather than less relevant, to the final decision.